SADBE treatment for congenital birthmarks
Treatments studied
Part of Cancer, Genetic & congenital, Skin clinical trials.
This study tests whether a topical drug called SADBE, applied to a congenital mole (a birthmark), can help reduce the mole before surgery. It is an early-stage trial, so it will help us learn if the treatment is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a congenital mole (birthmark) that is larger than about 2.4 inches (6 cm) across, and you must be planning surgery to remove part or all of it.
- You must not have taken medications that suppress the immune system (like steroids) in the past 4 weeks, except for asthma inhalers.
- You must not have a history of cancer, organ transplantation, or an immune-weakening disease such as HIV.
- You must not have severe health issues like insulin-treated diabetes, heart failure, a recent heart attack or stroke, unstable angina, or severe lung disease requiring oxygen.
- You must not be allergic to the study drug (SADBE) or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a precision medicine approach for people with melanoma. It studies how volatile organic compounds (substances your body releases) might help guide treatment for stage II, III, or IV melanoma.
This pilot study tests a gel called sirolimus to see if it can safely shrink or improve raised, dark birthmarks (epidermal nevi) in people 6 and older. The gel is applied directly to the birthmark, and the study will check how well it works and if it causes any side effects.
This study looks at how removing a large birthmark mole (a congenital melanocytic nevus) affects children’s quality of life and how much they feel stigmatized. It may help doctors understand what to expect and how to support kids before and after surgery.
This study compares removing the mole (halo nevus) versus leaving it alone in people who also have vitiligo. It aims to see if mole removal helps with skin repigmentation and disease control.
This study tests a new gel called LUT017 to see if it helps skin wounds heal better and faster after removal of harmless skin spots (like moles). It is for healthy adults having at least two benign skin lesions removed, and the gel is applied to the wounds to improve healing.
This study looks at the DNA and other biology from skin lesions (like melanoma or unusual pigmented moles) in children and teens. It aims to better understand what these tumors are and how they behave, using tissue samples collected during routine care.
Hear when a new Congenital Melanocytic Nevus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.